ClinicalTrials.gg
RecruitingNCT07190222THESEUSUpdated Oct 23, 2026

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

A Phase 3 interventional study of Lunsekimig and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Recruiting at 314 sites in 26 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 23, 2026First sites in 11 new countriesSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
942
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.

Planned enrollment
4th of 12
942 · median 937
Started
2025
with 3 others
Phase 3
8 of 15
3 open now
Registered
11th of 15
by date

Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 in phase 3, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, or all of them as a file.
02

Study summary

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.

Participation to the study consists of 3 periods:

  • Screening period of up to 4 weeks
  • Randomized intervention period of approximately 48 weeks
  • Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
Read the detailed description

All eligible participants will undergo subcutaneous administrations of lunsekimig or matching placebo during a 48-weeks treatment period

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 40 to 80 years of age
  • Physician diagnosed (COPD) ≥1 year
  • Post-bronchodilator (post-BD FEV1) ≥ 20% and ≤ 70% of predicted value and FEV1/FVC (forced expiratory volume in 1 second /forced vital capacity) \<0.70
  • Former or current smokers ≥10 pack-years
  • Chronic Airways Assessment Test (CAAT) ≥10
  • ≥2 moderate or ≥1 severe COPD exacerbations in the prior year
  • Triple (ICS+LABA+LAMA) COPD therapy ≥12 consecutive weeks
  • EOS (blood eosinophil count) ≥ 150 cells/μL
  • 18.0 ≤ ≤ 40.0 kg/m2

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Asthma, including pediatric asthma, or asthma- overlap syndrome (ACOS)
  • Significant pulmonary disease other than COPD
  • Long-term oxygen therapy >4.0 L/min or requirement of >2.0 L/min to maintain oxygen saturation >88% at rest
  • Unstable disorder that can impact participants safety or study outcomes
  • Active or incompletely treated tuberculosis
  • Current or past
  • Concomitant therapies:

    • long-term macrolides or phosphodiesterase Type 3 (PDE-3) or PDE-4 inhibitors unless on stable therapy for > 6 months
    • any biologic therapy or systemic within 4 months or 5 half-lives prior to Screening

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
942 participants (estimated)

Study arms

  • Experimental
    Lunsekimig dose regimen A

    Participants will receive lunsekimig dose regimen A.

    Drug: Lunsekimig

  • Experimental
    Lunsekimig dose regimen B

    Participants will receive lunsekimig dose regimen B.

    Drug: Lunsekimig

  • Placebo comparator
    Placebo

    Participants will receive lunsekimig-matching placebo.

    Drug: Placebo

Interventions

  • Pharmaceutical form: solution for injection in prefilled syringe. Route of administration: Subcutaneous injection

    Also known as: SAR443765

  • DrugPlacebo

    Pharmaceutical form: solution for injection. Route of administration: Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations

    The annualized moderate or severe COPD exacerbation rate up to 48 weeks treatment period compared to placebo

    Time frame: From Baseline up to 48 weeks

Secondary outcomes

  1. Change from baseline in post-Bronchodilator Forced Expiratory Volume in 1 second (post-BD FEV1)

    The post-Bronchodilator Forced Expiratory Volume in 1 second is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

    Time frame: From Baseline up to 48 weeks

  2. Change from baseline in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1)

    The pre-Bronchodilator Forced Expiratory Volume in 1 second is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

    Time frame: From Baseline up to 48 weeks

  3. Change from baseline in the SGRQ-C total score

    The St. George's Respiratory Questionnaire for patients with chronic obstructive pulmonary disease is derived from the St. George's Respiratory Questionnaire (SGRQ) and is designed to measure and quantify health status in adult patients with chronic airflow limitation. A global score ranges from 0 to 100 with lower scores indicating better quality-of-life.

    Time frame: From Baseline up to 48 weeks

  4. SGRQ responder defined as an improvement of ≥4 points in the SGRQ-C total score

    Time frame: From Baseline up to 48 weeks

  5. Change from baseline in the Chronic airways assessment Test (CAAT) score

    The CAAT is an 8-item patient-reported outcome (PRO) measure designed to assess the impact of chronic airways diseases, including COPD, on patients' health status. The CAAT has a scoring range of 0-40, with higher scores indicating a greater impact of the disease on health status.

    Time frame: From Baseline up to 48 weeks

  6. CAAT responder defined as an improvement of ≥2 points in the CAAT total score

    Time frame: From Baseline up to 48 weeks

  7. Change from baseline in the E-RS:COPD total score

    The Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) is an 11-item patient-reported outcome (PRO) measure that evaluates the severity of respiratory symptoms in patients with stable COPD. The total score ranges from 0 to 40, with higher scores indicating more severe respiratory symptoms.

    Time frame: From Baseline up to 48 weeks

  8. E-RS:COPD responder defined as an improvement of ≥2 points in the E-RS:COPD total score

    Time frame: From Baseline up to 48 weeks

  9. Annualized rate of severe COPD exacerbations

    Time frame: From Baseline up to 48 weeks

  10. Time to first moderate or severe COPD exacerbation

    Time to first occurrence of moderate to severe COPD exacerbation up to 48 weeks

    Time frame: From Baseline up to 48 weeks

  11. Time to first severe COPD exacerbation

    Time to first occurrence of severe COPD exacerbation up to 48 weeks

    Time frame: From Baseline up to 48 weeks

  12. Incidence of participants with TEAEs, including AESIs, and SAEs

    Treatment-Emergent Adverse Events (TEAEs), Adverse events of Special Interest (AESIs), Serious Adverse Events (SAEs)

    Time frame: From Baseline up to 56 weeks

  13. Incidence of potentially clinically significant laboratory abnormalities

    Time frame: From Baseline up to 56 weeks

  14. Serum concentration of lunsekimig

    Time frame: From Baseline up to 48 weeks

  15. Incidence and titer of antidrug antibodies (ADAs)

    Time frame: From Baseline up to 48 weeks

07

Study locations

310 of 314 sites recruiting
  • University of Alabama at Birmingham- Site Number : 8400003
    Birmingham, Alabama 35233, United States
    Recruiting
  • Pulmonary Associates - Mobile- Site Number : 8400151
    Mobile, Alabama 36608, United States
    Recruiting
  • Tucson Clinical Research Institute- Site Number : 8400006
    Tucson, Arizona 85712, United States
    Recruiting
  • Ark Clinical Research- Site Number : 8400113
    Long Beach, California 90815, United States
    Recruiting
  • Inglewood Clinical- Site Number : 8400074
    Los Angeles, California 90056, United States
    Recruiting
  • Alliance Clinical - West Hills- Site Number : 8400067
    Los Angeles, California 91307, United States
    Recruiting
  • California Medical Research Associates - Northridge- Site Number : 8400089
    Northridge, California 91324, United States
    Recruiting
  • Acclaim Clinical Research- Site Number : 8400068
    San Diego, California 92120, United States
    Completed

    Not enrolling at this site — choose another above.

  • Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8400005
    Boulder, Colorado 80301, United States
    Recruiting
  • Critical Care Pulmonary & Sleep Associates- Site Number : 8400081
    Lakewood, Colorado 80228, United States
    Recruiting
  • Howard University Hospital- Site Number : 8400080
    Washington D.C., District of Columbia 20060, United States
    Recruiting
  • Meris Clinical Research- Site Number : 8400153
    Brandon, Florida 33511, United States
    Recruiting
  • Hillcrest Medical Research- Site Number : 8400082
    DeLand, Florida 32720, United States
    Recruiting
  • Finlay Medical Research - Greenacres- Site Number : 8400107
    Greenacres City, Florida 33467, United States
    Recruiting
  • Direct Helpers Research Center- Site Number : 8400057
    Hialeah, Florida 33012, United States
    Recruiting
  • University of Florida - Jacksonville- Site Number : 8400126
    Jacksonville, Florida 32209, United States
    Recruiting
  • Salud Clinical Services- Site Number : 8400109
    Lehigh Acres, Florida 33936, United States
    Recruiting
  • Pulmonary Specialists of the Palm Beaches- Site Number : 8400017
    Loxahatchee Groves, Florida 33470, United States
    Recruiting
  • Elite Clinical Research - Miami- Site Number : 8400167
    Miami, Florida 33144, United States
    Recruiting
  • DL Research Solutions- Site Number : 8400140
    Miami, Florida 33155, United States
    Recruiting
  • Phoenix Medical Research - Miami - 24th Street- Site Number : 8400027
    Miami, Florida 33165, United States
    Recruiting
  • Professional Research Center- Site Number : 8400046
    Miami, Florida 33172, United States
    Recruiting
  • Research Institute of South Florida- Site Number : 8400028
    Miami, Florida 33173, United States
    Recruiting
  • Innovations Biotech- Site Number : 8400019
    Miami, Florida 33186, United States
    Recruiting
  • Heuer M.D. Research- Site Number : 8400018
    Orlando, Florida 32819, United States
    Recruiting
  • Florida Institute for Clinical Research- Site Number : 8400001
    Orlando, Florida 32825, United States
    Recruiting
  • Avanza Medical Research Center- Site Number : 8400015
    Pensacola, Florida 32503, United States
    Recruiting
  • Hull and Hull Medical Specialists- Site Number : 8400002
    Plantation, Florida 33324, United States
    Recruiting
  • Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400041
    Sarasota, Florida 34239, United States
    Recruiting
  • Stat Care Pulmonary and Sleep- Site Number : 8400138
    St. Petersburg, Florida 33709, United States
    Recruiting
  • Better Life Clinical Research- Site Number : 8400152
    Tampa, Florida 33607, United States
    Recruiting
  • Vicis Clinical Research- Site Number : 8400158
    Tampa, Florida 33615, United States
    Recruiting
  • Appalachian Clinical Research- Site Number : 8400060
    Adairsville, Georgia 30103, United States
    Recruiting
  • Christie Clinic in Champaign on University- Site Number : 8400023
    Champaign, Illinois 61820, United States
    Recruiting
  • Sneeze Wheeze & Itch Associates- Site Number : 8400020
    Normal, Illinois 61761, United States
    Recruiting
  • Peoria Pulmonary Associates Ltd- Site Number : 8400095
    Peoria, Illinois 61603, United States
    Recruiting
  • Asha Clinical Research - Munster- Site Number : 8400115
    Hammond, Indiana 46324, United States
    Recruiting
  • Ochsner LSU Health Shreveport - Academic Medical Center- Site Number : 8400083
    Shreveport, Louisiana 71103, United States
    Recruiting
  • Care Access - Shreveport - Youree Drive- Site Number : 8400007
    Shreveport, Louisiana 71105, United States
    Recruiting
  • Johns Hopkins Bayview Medical Center- Site Number : 8400076
    Baltimore, Maryland 21224, United States
    Recruiting
  • Lucida Clinical Trials- Site Number : 8400101
    New Bedford, Massachusetts 02740, United States
    Recruiting
  • Vitalis Clinical Research Center- Site Number : 8400040
    Allen Park, Michigan 48101, United States
    Recruiting
  • Bolt Clinical Research- Site Number : 8400086
    Brighton, Michigan 48116, United States
    Recruiting
  • Henry Ford Hospital- Site Number : 8400058
    Detroit, Michigan 48202, United States
    Recruiting
  • Pulmonary Research Institute of Southeast Michigan - Farmington Hills- Site Number : 8400161
    Farmington Hills, Michigan 48336, United States
    Recruiting
  • Hannibal Regional Healthcare System- Site Number : 8400035
    Hannibal, Missouri 63401, United States
    Recruiting
  • Washington University- Site Number : 8400144
    St Louis, Missouri 63110, United States
    Recruiting
  • Excel Clinical Research - Las Vegas- Site Number : 8400070
    Las Vegas, Nevada 89109, United States
    Recruiting
  • AB Clinical Trials- Site Number : 8400075
    Las Vegas, Nevada 89119, United States
    Completed

    Not enrolling at this site — choose another above.

  • Bioluminux Clinical Research - Hamilton, New Jersey- Site Number : 8400037
    Hamilton, New Jersey 08690, United States
    Recruiting
  • Rutgers Institute For Infectious & Inflammatory Diseases (I3d)- Site Number : 8400093
    Newark, New Jersey 07103, United States
    Recruiting
  • Trinity Medical, WNY- Site Number : 8400157
    Buffalo, New York 14215, United States
    Recruiting
  • Mid Hudson Medical Research - New Windsor- Site Number : 8400004
    New Windsor, New York 12553, United States
    Recruiting
  • East Carolina University- Site Number : 8400102
    Greenville, North Carolina 27858, United States
    Recruiting
  • Piedmont Healthcare - Family Medicine- Site Number : 8400022
    Statesville, North Carolina 28625, United States
    Completed

    Not enrolling at this site — choose another above.

  • All-Trials Clinical Research- Site Number : 8400008
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Asthma & Allergy Center - Toledo- Site Number : 8400110
    Toledo, Ohio 43617, United States
    Recruiting
  • Layrek Clinical Research- Site Number : 8400066
    Tulsa, Oklahoma 74133, United States
    Recruiting
  • The Oregon Clinic - Portland - Northwest 22nd Avenue- Site Number : 8400065
    Portland, Oregon 97210, United States
    Recruiting
  • Suburban Research Associates - Media- Site Number : 8400143
    Media, Pennsylvania 19063, United States
    Recruiting
  • MedTrial- Site Number : 8400010
    Columbia, South Carolina 29204, United States
    Recruiting
  • Chattanooga Research and Medicine- Site Number : 8400026
    Chattanooga, Tennessee 37404, United States
    Recruiting
  • Premier Research Center, Llc- Site Number : 8400146
    Hendersonville, Tennessee 37075, United States
    Recruiting
  • Solace Clinical Research- Site Number : 8400087
    Austin, Texas 78759, United States
    Recruiting
  • IntraCare- Site Number : 8400034
    Dallas, Texas 75254, United States
    Recruiting
  • Premier Pulmonary Critical Care and Sleep- Site Number : 8400111
    Denison, Texas 75020, United States
    Recruiting
  • El Paso Pulmonary Association- Site Number : 8400033
    El Paso, Texas 79902, United States
    Recruiting
  • Axsendo Clinical Research - Houston- Site Number : 8400054
    Houston, Texas 77058, United States
    Completed

    Not enrolling at this site — choose another above.

  • Se Houston- Site Number : 8400120
    Houston, Texas 77061, United States
    Recruiting
  • Aavon Clinical Trials, Llc- Site Number : 8400166
    Houston, Texas 77074, United States
    Recruiting
  • Synergy Group US - Missouri City- Site Number : 8400119
    Missouri City, Texas 77459, United States
    Recruiting
  • Synergy Group US - Missouri City- Site Number : 8400133
    Missouri City, Texas 77459, United States
    Recruiting
  • Elligo Health Care, Hillcroft Medical Clinic Association- Site Number : 8400053
    Sugar Land, Texas 77478, United States
    Recruiting
  • Medrasa Clinical Research - Wylie- Site Number : 8400124
    Wylie, Texas 75098, United States
    Recruiting
  • Rheumatology & Pulmonary Clinic- Site Number : 8400012
    Beckley, West Virginia 25801, United States
    Recruiting
  • Investigational Site Number : 0320011
    Berazategui, Buenos Aires 1886, Argentina
    Recruiting
  • Investigational Site Number : 0320004
    Buenos Aires, 1006, Argentina
    Recruiting
  • Investigational Site Number : 0320002
    Buenos Aires, 1023, Argentina
    Recruiting
  • Investigational Site Number : 0320005
    Buenos Aires, 1121, Argentina
    Recruiting
  • Investigational Site Number : 0320003
    Buenos Aires, 1182, Argentina
    Recruiting
  • Investigational Site Number : 0320006
    Buenos Aires, 1280, Argentina
    Recruiting
  • Investigational Site Number : 0320001
    Buenos Aires, 1414, Argentina
    Recruiting
  • Investigational Site Number : 0320012
    Buenos Aires, 1638, Argentina
    Recruiting
  • Investigational Site Number : 0320009
    Córdoba, 5003, Argentina
    Recruiting
  • Investigational Site Number : 0320007
    Mendoza, 5500, Argentina
    Recruiting
  • Investigational Site Number : 0320008
    Mendoza, 5500, Argentina
    Recruiting
  • Investigational Site Number : 0320010
    Santa Fe, 3000, Argentina
    Recruiting
  • Investigational Site Number : 0360007
    Coffs Harbour, New South Wales 2450, Australia
    Recruiting
  • Investigational Site Number : 0360008
    Tiwi, Northern Territory 0810, Australia
    Recruiting
  • Investigational Site Number : 0360006
    South Brisbane, Queensland 4101, Australia
    Recruiting
  • Investigational Site Number : 0360004
    Townsville, Queensland 4814, Australia
    Recruiting
  • Investigational Site Number : 0360002
    Traralgon, Victoria 3844, Australia
    Recruiting
  • Investigational Site Number : 0360001
    Osborne Park, Western Australia 6017, Australia
    Recruiting
  • Investigational Site Number : 5540004
    Dunedin, 9016, Australia
    Recruiting
  • Universidade Federal de Goias- Site Number : 0760002
    Goiânia, Goiás 74605-020, Brazil
    Recruiting
  • Santa Casa de Misericordia de Belo Horizonte- Site Number : 0760004
    Belo Horizonte, Minas Gerais 30150-221, Brazil
    Recruiting
  • WM Pesquisas Clínicas em Doenças Respiratórias- Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 91010-006, Brazil
    Recruiting
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos - São Bernardo do Campo- Site Number : 0760001
    São Bernardo do Campo, São Paulo 09715-090, Brazil
    Recruiting
  • IBCC - Núcleo de Pesquisa e Ensino- Site Number : 0760005
    São Paulo, 04014-002, Brazil
    Recruiting
  • Investigational Site Number : 1240051
    Kelowna, British Columbia V1Y 4N7, Canada
    Recruiting

Showing the first 100 of 314 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Nov 2029, 50 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 50 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 24, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Nov 27, 2029
CompletionEst.
Jan 22, 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
109 sites added, 9 sites removed — first sites in Czechia, Germany, Israel, Lithuania, Mexico and 6 more
All 11 countries

Czechia, Germany, Israel, Lithuania, Mexico, Netherlands, Norway, Poland, Romania, Slovakia, Spain

. 2 sites changed recruiting status (2 now completed)
Show 2 sites
  • Acclaim Clinical Research- Site Number : 8400068 · San Diego, United StatesRecruiting→Completed
  • Piedmont Healthcare - Family Medicine- Site Number : 8400022 · Statesville, United StatesRecruiting→Completed
Show 109 added (24 United States, 11 Germany, 10 Israel, 9 Spain, 7 Netherlands, 7 Poland, 6 Czechia, 6 Mexico, 5 Greece, 4 China, 4 Norway, 3 Romania, 3 Slovakia, 3 South Africa, 1 Australia, 1 Brazil, 1 Canada, 1 Lithuania, 1 Malaysia, 1 Singapore, 1 Taiwan)
  • Pulmonary Associates - Mobile- Site Number : 8400151 · Mobile, United States
  • Inglewood Clinical- Site Number : 8400074 · Los Angeles, United States
  • Acclaim Clinical Research- Site Number : 8400068 · San Diego, United States
  • Meris Clinical Research- Site Number : 8400153 · Brandon, United States
  • Hillcrest Medical Research- Site Number : 8400082 · DeLand, United States
  • University of Florida - Jacksonville- Site Number : 8400126 · Jacksonville, United States
  • Salud Clinical Services- Site Number : 8400109 · Lehigh Acres, United States
  • Elite Clinical Research - Miami- Site Number : 8400167 · Miami, United States
  • Heuer M.D. Research- Site Number : 8400018 · Orlando, United States
  • Stat Care Pulmonary and Sleep- Site Number : 8400138 · St. Petersburg, United States
  • Vicis Clinical Research- Site Number : 8400158 · Tampa, United States
  • Ochsner LSU Health Shreveport - Academic Medical Center- Site Number : 8400083 · Shreveport, United States
  • Johns Hopkins Bayview Medical Center- Site Number : 8400076 · Baltimore, United States
  • Henry Ford Hospital- Site Number : 8400058 · Detroit, United States
  • Pulmonary Research Institute of Southeast Michigan - Farmington Hills- Site Number : 8400161 · Farmington Hills, United States
  • University of Missouri Health Care - Children's Hospital- Site Number : 8400150 · Columbia, United States
  • Washington University- Site Number : 8400144 · St Louis, United States
  • Rutgers Institute For Infectious & Inflammatory Diseases (I3d)- Site Number : 8400093 · Newark, United States
  • Trinity Medical, WNY- Site Number : 8400157 · Buffalo, United States
  • Suburban Research Associates - Media- Site Number : 8400143 · Media, United States
  • Premier Research Center, Llc- Site Number : 8400146 · Hendersonville, United States
  • Solace Clinical Research- Site Number : 8400087 · Austin, United States
  • Se Houston- Site Number : 8400120 · Houston, United States
  • Aavon Clinical Trials, Llc- Site Number : 8400166 · Houston, United States
  • Investigational Site Number : 0360007 · Coffs Harbour, Australia
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos - São Bernardo do Campo- Site Number : 0760001 · São Bernardo do Campo, Brazil
  • Investigational Site Number : 1240045 · Niagara Falls, Canada
  • Investigational Site Number : 1560062 · Changchun, China
  • Investigational Site Number : 1560046 · Huai'an, China
  • Investigational Site Number : 1560027 · Nanning, China
  • …and 79 more on the registry record
Show 9 removed
  • Inglewood Clinical- Site Number : 8400074 · Inglewood, United States
  • SE Houston- Site Number : 8400120 · Houston, United States
  • Centro Multidisciplinar de Estudos Clínicos- Site Number : 0760001 · São Bernardo do Campo, Brazil
  • Investigational Site Number : 1560046 · Huaian City, China
  • Investigational Site Number : 7100001 · Cape Town, South Africa
  • Investigational Site Number : 1580006 · Guishan, Taiwan
  • University of Missouri Health Care - Children's Hospital- Site Number : 8400150 · Columbia, United States
  • Investigational Site Number : 2760002 · Leipzig, Germany
  • Investigational Site Number : 7240007 · Madrid, Spain
across 2 updates, Oct 1, 2026 – Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    2 sites added, 3 sites removed. 2 sites changed recruiting status (2 now completed)
    Show 2 sites
    • Acclaim Clinical Research- Site Number : 8400068 · San Diego, United StatesRecruiting→Completed
    • Piedmont Healthcare - Family Medicine- Site Number : 8400022 · Statesville, United StatesRecruiting→Completed
    Show 2 added (1 Greece, 1 Spain)
    • Investigational Site Number : 3000003 · Alexandroupoli, Greece
    • Investigational Site Number : 7240007 · Chamberí, Spain
    Show 3 removed
    • University of Missouri Health Care - Children's Hospital- Site Number : 8400150 · Columbia, United States
    • Investigational Site Number : 2760002 · Leipzig, Germany
    • Investigational Site Number : 7240007 · Madrid, Spain
    + 2 other changes: verification date and references
  2. Oct 1, 2026
    107 sites added, 6 sites removed — first sites in Czechia, Germany, Israel, Lithuania, Mexico and 6 more
    All 11 countries

    Czechia, Germany, Israel, Lithuania, Mexico, Netherlands, Norway, Poland, Romania, Slovakia, Spain

    Show 107 added (24 United States, 11 Germany, 10 Israel, 8 Spain, 7 Netherlands, 7 Poland, 6 Czechia, 6 Mexico, 4 China, 4 Greece, 4 Norway, 3 Romania, 3 Slovakia, 3 South Africa, 1 Australia, 1 Brazil, 1 Canada, 1 Lithuania, 1 Malaysia, 1 Singapore, 1 Taiwan)
    • Pulmonary Associates - Mobile- Site Number : 8400151 · Mobile, United States
    • Inglewood Clinical- Site Number : 8400074 · Los Angeles, United States
    • Acclaim Clinical Research- Site Number : 8400068 · San Diego, United States
    • Meris Clinical Research- Site Number : 8400153 · Brandon, United States
    • Hillcrest Medical Research- Site Number : 8400082 · DeLand, United States
    • University of Florida - Jacksonville- Site Number : 8400126 · Jacksonville, United States
    • Salud Clinical Services- Site Number : 8400109 · Lehigh Acres, United States
    • Elite Clinical Research - Miami- Site Number : 8400167 · Miami, United States
    • Heuer M.D. Research- Site Number : 8400018 · Orlando, United States
    • Stat Care Pulmonary and Sleep- Site Number : 8400138 · St. Petersburg, United States
    • Vicis Clinical Research- Site Number : 8400158 · Tampa, United States
    • Ochsner LSU Health Shreveport - Academic Medical Center- Site Number : 8400083 · Shreveport, United States
    • Johns Hopkins Bayview Medical Center- Site Number : 8400076 · Baltimore, United States
    • Henry Ford Hospital- Site Number : 8400058 · Detroit, United States
    • Pulmonary Research Institute of Southeast Michigan - Farmington Hills- Site Number : 8400161 · Farmington Hills, United States
    • University of Missouri Health Care - Children's Hospital- Site Number : 8400150 · Columbia, United States
    • Washington University- Site Number : 8400144 · St Louis, United States
    • Rutgers Institute For Infectious & Inflammatory Diseases (I3d)- Site Number : 8400093 · Newark, United States
    • Trinity Medical, WNY- Site Number : 8400157 · Buffalo, United States
    • Suburban Research Associates - Media- Site Number : 8400143 · Media, United States
    • Premier Research Center, Llc- Site Number : 8400146 · Hendersonville, United States
    • Solace Clinical Research- Site Number : 8400087 · Austin, United States
    • Se Houston- Site Number : 8400120 · Houston, United States
    • Aavon Clinical Trials, Llc- Site Number : 8400166 · Houston, United States
    • Investigational Site Number : 0360007 · Coffs Harbour, Australia
    • CEMEC - Centro Multidisciplinar de Estudos Clínicos - São Bernardo do Campo- Site Number : 0760001 · São Bernardo do Campo, Brazil
    • Investigational Site Number : 1240045 · Niagara Falls, Canada
    • Investigational Site Number : 1560062 · Changchun, China
    • Investigational Site Number : 1560046 · Huai'an, China
    • Investigational Site Number : 1560027 · Nanning, China
    • …and 77 more on the registry record
    Show 6 removed
    • Inglewood Clinical- Site Number : 8400074 · Inglewood, United States
    • SE Houston- Site Number : 8400120 · Houston, United States
    • Centro Multidisciplinar de Estudos Clínicos- Site Number : 0760001 · São Bernardo do Campo, Brazil
    • Investigational Site Number : 1560046 · Huaian City, China
    • Investigational Site Number : 7100001 · Cape Town, South Africa
    • Investigational Site Number : 1580006 · Guishan, Taiwan

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07190222
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Sep 17, 2025
Primary completion
Nov 27, 2029 (estimated)
Completion
Jan 22, 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lunsekimig

Start the discussion